Importantly, this knowledge on “T cell ­exhaustion” and the implication of iRs has had full impact on therapeutic strategies, with the breakthrough of monoclonal antibodies that block iRs (also referred to as “checkpoint blockade”) to restore T cell function and yielding unprecedented clinical improvements on overall survival of cancer patients. This evidence concerns the gene IARS1 and cancer.